In the routine clinical practice, HER2 quantification is required for selecting patients with breast cancer who are eligible for trastuzumab therapy because this drug is effective only in HER2-overexpressing tumors [8], [10], [22], [11]. Here, ERBB2 is linked to breast carcinoma.